Guangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa

Bulletin Express02-04 23:04

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa. This core product targets companion animal diabetes, and Phase I clinical trials are anticipated to begin in the first quarter of 2026.

Management believes that research and development of diabetic medication for companion animals present significant prospects, aligning with the group’s long-term business strategy and offering potential groundwork for future expansion into companion animal drug products. According to pre-clinical trial data, Efsubaglutide Alfa showed positive efficacy and safety results in diabetic management for companion animals, which supports subsequent clinical trials and future registration applications.

A cautionary statement indicates that there is no guarantee of the eventual success of developing or marketing Efsubaglutide Alfa for companion animal diabetes. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143745026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143745026","market":"hk","top_or_hot":-1,"title":"Guangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa. This core product targets companion animal diabetes, and Phase I clinical trials are anticipated to begin in the first quarter of 2026.</p>\n<p>Management believes that research and development of diabetic medication for companion animals present significant prospects, aligning with the group’s long-term business strategy and offering potential groundwork for future expansion into companion animal drug products. According to pre-clinical trial data, Efsubaglutide Alfa showed positive efficacy and safety results in diabetic management for companion animals, which supports subsequent clinical trials and future registration applications.</p>\n<p>A cautionary statement indicates that there is no guarantee of the eventual success of developing or marketing Efsubaglutide Alfa for companion animal diabetes. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-04 23:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa. This core product targets companion animal diabetes, and Phase I clinical trials are anticipated to begin in the first quarter of 2026.</p>\n<p>Management believes that research and development of diabetic medication for companion animals present significant prospects, aligning with the group’s long-term business strategy and offering potential groundwork for future expansion into companion animal drug products. According to pre-clinical trial data, Efsubaglutide Alfa showed positive efficacy and safety results in diabetic management for companion animals, which supports subsequent clinical trials and future registration applications.</p>\n<p>A cautionary statement indicates that there is no guarantee of the eventual success of developing or marketing Efsubaglutide Alfa for companion animal diabetes. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1143745026","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143745026","pubTimestamp":1770217456,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"广州英诺药业(2591)公布Efsubaglutide Alfa的研究性新兽药申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa. This core product targets companion animal diabetes, and Phase I clinical trials are anticipated to begin in the first quarter of 2026.\nManagement believes that research and development of diabetic medication for companion animals present significant prospects, aligning with the group’s long-term business strategy and offering potential groundwork for future expansion into companion animal drug products. According to pre-clinical trial data, Efsubaglutide Alfa showed positive efficacy and safety results in diabetic management for companion animals, which supports subsequent clinical trials and future registration applications.\nA cautionary statement indicates that there is no guarantee of the eventual success of developing or marketing Efsubaglutide Alfa for companion animal diabetes. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143745026","isCrawlerRequest":true}